title: Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
abstract: Previous studies examining combination therapy for invasive pulmonary aspergillosis (IPA) have revealed conflicting results, including antagonism, indifference, and enhanced effects. The most commonly employed combination for this infection includes a mold-active triazole and echinocandin. Few studies have evaluated combination therapy from a pharmacodynamic (PD) perspective, and even fewer have examined combination therapy against both wild-type and azole-resistant Cyp51 mutant isolates. The current studies aim to fill this gap in knowledge. Four Aspergillus fumigatus isolates were utilized, including a wild-type strain, an Fks1 mutant (posaconazole susceptible and caspofungin resistant), and two Cyp51 mutants (posaconazole resistant). A neutropenic murine model of IPA was used for the treatment studies. The dosing design included monotherapy with posaconazole, monotherapy with caspofungin, and combination therapy with both. Efficacy was determined using quantitative PCR, and results were normalized to known quantities of conidia (conidial equivalents [CE]). The static dose, 1-log kill dose, and associated PD target area under the curve (AUC)/MIC ratio were determined for monotherapy and combination therapy. Monotherapy experiments revealed potent activity for posaconazole, with reductions of 3 to 4 log10 Aspergillus CE/ml with the two "low"-MIC isolates. Posaconazole alone was less effective for the two isolates with higher MICs. Caspofungin monotherapy did not produce a significant decrease in fungal burden for any strain. Combination therapy with the two antifungals did not enhance efficacy for the two posaconazole-susceptible isolates. However, the drug combination produced synergistic activity against both posaconazole-resistant isolates. Specifically, the combination resulted in a 1- to 2-log10 decline in burden that would not have been predicted based on the monotherapy results for each drug. This corresponded to a reduction in the free-drug posaconazole AUC/MIC ratio needed for stasis of up to 17-fold. The data suggest that combination therapy using a triazole and an echinocandin may be a beneficial treatment strategy for triazole-resistant isolates.
authors: University of Wisconsin, Madison, Wisconsin, USA.
authors: Alexander J
authors: AJ
authors: Lepak
authors: Karen
authors: K
authors: Marchillo
authors: Jamie
authors: J
authors: VanHecker
authors: David R
authors: DR
authors: Andes
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D000077336:Caspofungin; D004305:Dose-Response Relationship, Drug; D025141:Drug Resistance, Fungal / Q000187:drug effects; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D055666:Lipopeptides; D051379:Mice; D008826:Microbial Sensitivity Tests; D013172:Spores, Fungal / Q000187:drug effects* / Q000254:growth & development; D014230:Triazoles / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D014230:Triazoles; C101425:posaconazole; D000077336:Caspofungin
references: Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506
references: 20385855
references: Emerg Infect Dis. 2009 Jul;15(7):1068-76
references: 19624922
references: Circulation. 2005 Jun 14;111(23):e394-434
references: 15956145
references: Antimicrob Agents Chemother. 2006 Feb;50(2):469-73
references: 16436698
references: Clin Infect Dis. 2010 Apr 15;50(8):1101-11
references: 20218876
references: Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47
references: 23959322
references: Transplantation. 2006 Feb 15;81(3):320-6
references: 16477215
references: Pharmacol Rev. 1995 Jun;47(2):331-85
references: 7568331
references: Future Microbiol. 2011 Nov;6(11):1229-32
references: 22082283
references: Expert Rev Anti Infect Ther. 2007 Oct;5(5):883-92
references: 17914921
references: Antimicrob Agents Chemother. 2013 Jan;57(1):579-85
references: 23147740
references: PLoS One. 2012;7(4):e35478
references: 22536390
references: Antimicrob Agents Chemother. 1998 Sep;42(9):2375-9
references: 9736566
references: J Clin Pharm Ther. 2010 Feb;35(1):49-53
references: 20175811
references: Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81
references: 11709327
references: Clin Infect Dis. 2007 Jan 1;44(1):2-12
references: 17143808
references: Cancer. 2006 Dec 15;107(12):2888-97
references: 17103444
references: Curr Fungal Infect Rep. 2010 May 1;4(2):87-95
references: 20574543
references: N Engl J Med. 2002 Aug 8;347(6):408-15
references: 12167683
references: Antimicrob Agents Chemother. 2008 Jul;52(7):2593-8
references: 18474582
references: J Infect Dis. 2011 May 1;203(9):1324-32
references: 21357943
references: Clin Infect Dis. 2008 Jun 15;46(12):1889-901
references: 18466092
references: Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68
references: 16304173
references: Clin Infect Dis. 2010 Jun 15;50(12):1559-67
references: 20450350
references: Med Mycol. 2011 Apr;49 Suppl 1:S90-5
references: 20795765
references: Clin Infect Dis. 2010 Feb 1;50(3):291-322
references: 20047480
references: Clin Infect Dis. 2008 Feb 1;46(3):327-60
references: 18177225
references: Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5
references: 22825124
references: J Infect. 2006 Nov;53(5):337-49
references: 16678903
references: Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8
references: 12121933
references: Antimicrob Agents Chemother. 2004 Jan;48(1):137-42
references: 14693531
references: Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S188-224
references: 12975752
references: Clin Microbiol Infect. 2004 Oct;10(10):925-8
references: 15373889
references: Antimicrob Agents Chemother. 2005 Sep;49(9):3697-701
references: 16127042
references: J Antimicrob Chemother. 2011 Jun;66(6):1324-31
references: 21486855
references: Antimicrob Agents Chemother. 2008 Nov;52(11):4178-80
references: 18725439
references: Antimicrob Agents Chemother. 2002 Jan;46(1):12-23
references: 11751105
references: MMWR Recomm Rep. 2003 Jun 20;52(RR-11):1-77
references: 12836625
references: Antimicrob Agents Chemother. 2009 May;53(5):2005-13
references: 19237647
references: J Clin Microbiol. 1987 May;25(5):931-2
references: 3294892
references: Transpl Infect Dis. 2009 Feb;11(1):89-93
references: 18983417
references: Antimicrob Agents Chemother. 2010 Nov;54(11):4758-64
references: 20733046
references: J Antimicrob Chemother. 2013 Feb;68(2):385-93
references: 23129729
references: Clin Infect Dis. 2004 Sep 15;39(6):797-802
references: 15472810
references: Clin Infect Dis. 2010 Apr 15;50(8):1091-100
references: 20218877
references: Clin Infect Dis. 2005 Nov 15;41(10):1448-52
references: 16231256
references: Antimicrob Agents Chemother. 2009 Jun;53(6):2382-91
references: 19307368
references: Antimicrob Agents Chemother. 2010 Feb;54(2):860-5
references: 19917751
references: J Infect Dis. 2008 Jul 15;198(2):186-92
references: 18500936
references: Crit Care Clin. 2011 Apr;27(2):e1-27
references: 21440195
references: PLoS Med. 2008 Nov 11;5(11):e219
references: 18998768
references: J Clin Microbiol. 2009 May;47(5):1325-32
references: 19261786
references: Med Mycol. 2005 May;43 Suppl 1:S295-8
references: 16110823